Taysha Gene Therapies Inc (TSHA)
2.57
-0.01
(-0.39%)
USD |
NASDAQ |
May 03, 16:00
2.575
0.00 (0.00%)
After-Hours: 20:00
Taysha Gene Therapies Cash from Investing (TTM): -7.352M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -7.352M |
| September 30, 2023 | -9.712M |
| June 30, 2023 | -9.242M |
| March 31, 2023 | -17.40M |
| December 31, 2022 | -24.93M |
| September 30, 2022 | -31.08M |
| June 30, 2022 | -32.06M |
| Date | Value |
|---|---|
| March 31, 2022 | -32.45M |
| December 31, 2021 | -21.55M |
| September 30, 2021 | -19.08M |
| June 30, 2021 | -15.11M |
| March 31, 2021 | -9.616M |
| December 31, 2020 | -9.082M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-32.45M
Minimum
Mar 2022
-7.352M
Maximum
Dec 2023
-18.36M
Average
-17.40M
Median
Mar 2023
Cash from Investing (TTM) Benchmarks
| Aquestive Therapeutics Inc | -0.995M |
| Lifecore Biomedical Inc | -4.153M |
| Relmada Therapeutics Inc | 50.45M |
| ACADIA Pharmaceuticals Inc | 32.00M |
| Cyclacel Pharmaceuticals Inc | -0.006M |